AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO

RTTNews | 934 days ago
Stocktwits
AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO

(RTTNews) - AbbVie, Inc. (ABBV) announced Tuesday that its board of directors has unanimously selected Robert Michael, AbbVie's current president and chief operating officer, to succeed Richard Gonzalez as the company's chief executive officer.

Gonzalez, who has served as CEO since the company's formation in 2013, will retire from the role of CEO and become executive chairman of the board of directors, effective July 1, 2024. Additionally, the board has appointed Michael as a member of the board of directors effective July 1, 2024.

A member of AbbVie's Executive Leadership Team, Michael was previously served as vice chairman and president. Michael has 31 years of experience including leadership roles across multiple businesses, including pharmaceuticals, aesthetics, diagnostics, diabetes care and nutrition.

Michael began his career with Abbott as a member of the financial development program and ultimately served as division controller, nutrition supply chain and division controller, molecular diagnostics, among other roles.

Upon AbbVie's separation from Abbott in 2013, Michael established and led the company's first financial planning organization as vice president, AbbVie financial planning and analysis. He then held a series of leadership roles of increasing responsibility. He was appointed CFO in 2018, vice chairman, finance and commercial operations in 2021, vice chairman and president in 2022 and president and chief operating officer in 2023.

Tags: ABBV
Stocktwits
read more
AbbVie To Acquire Immunology Drug Maker Apogee For $10.9 Bln Cash; Shares Climb

AbbVie To Acquire Immunology Drug Maker Apogee For $10.9 Bln Cash; Shares Climb

Biopharmaceutical company AbbVie, Inc. announced Monday an agreement to acquire inflammatory and immunological drug maker Apogee Therapeutics for $135.11 per share in cash, for a total equity value of around $10.9 billion. Following the news, AbbVie shares are gaining 4 percent, while Apogee shares are surging around 47 percent.
RTTNews | 80 days ago
AbbVie Boosts FY24 Outlook - Update

AbbVie Boosts FY24 Outlook - Update

While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2024.
RTTNews | 778 days ago
AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis

AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis

AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ 15 mg, once daily) for the treatment of adult patients with giant cell arteritis (GCA).
RTTNews | 791 days ago
AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients

AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients

AbbVie, Inc. (ABBV) announced Tuesday that a new weight-based oral solution RINVOQ LQ (upadacitinib) is now available as an option for pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
RTTNews | 829 days ago
AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin

AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin

Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The trial demonstrated compelling clinical benefits across key endpoints.
RTTNews | 1017 days ago
AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint

AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint

AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.
RTTNews | 1078 days ago
Tools
Kalender Ekonomi
Jam pasar
Suku bunga
Kalender hari libur
Pasar Valas
Forex Volatility
Forex Correlation
Berita Forex
Analisis Forex
COT Data
Likuiditas
Kalkulator Forex
Forex Heat Map
Indikator ekonomi Konverter mata uang
Komunitas
Komunitas
Sistems
Most Popular Systems
Strategies
Kontes
Forex Charts
Forex Sentiment
Indikator Sentimen
Reviu
Pialang
Perusahaan Prop Trading
VPS Services
Signal Providers
EA Programming Services
Program Afiliasi
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Bursa Kripto
Kursus trading
Pelacak Portofolio Saham
Pialang
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions
Siaran Pers
Platform
Widget
Features
API
RSS
Stock Portfolio
Affiliate Software
Grafik Lanjutan
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2026 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.